Article preview from "The Gray Sheet"- January 21, 2014
Covidien says its decision to halt development of its OneShot renal denervation system was made prior to Medtronic’s recent announcement that its Symplicity device missed its endpoint. Covidien cites slower-than-expected development of the renal denervation market.
Covidien Quits Renal Denervation Race, Stops OneShot Development
Article preview from "The Gray Sheet"- January 21, 2014
Covidien PLC announced Jan. 21 that it will stop developing its OneShot renal denervation system for treatment of hypertension.
The decision comes less than two weeks after Medtronic Inc.announced that the sham-controlled SYMPLICITY HTN-3
trial of its Symplicity renal denervation system missed its primary efficacy endpoint, casting doubt not only over the future of the Symplicity program, but over the efficacy of renal denervation as a therapy for hypertension in general.
However, Covidien maintains that their decision to exit the renal denervation market was not related to the failure of the SYMPLICITY HTN-3 trial. In a release, the company says it is halting OneShot “primarily in response to slower-than-expected development of the renal denervation market.”
Mark Turco, chief medical officer for Covidien Vascular said in an interview, “We have continually looked at all over vascular therapy opportunities and we continued to look [at] our OneShot program well before the Medtronic announcement. The decision that was announced today very much preceded the Medtronic announcements around their clinical trial, SYMPLICITY HTN-3.”
Continued...
To read this article in its entirety,Purchase nowas a PDF and receive it immediately via email. Or get it FREE when you subscribe to "The Gray Sheet".
Plus:
To find out about more about more about Elsevier Business Intelligence's medical device publications and databases, multi-user access and/or advertising with Medical Devices Today, please contact Kristy Kennedy at (480) 985-9512
Comments